Cardlytics, Inc. (NASDAQ:CDLX – Get Rating) traded up 9.8% during Tuesday’s midday session. The stock traded as high as $25.50 and last traded at $25.45. 9,038 shares were traded at midday, down 98% from the average session volume of 454,290 shares. The stock previously closed at $23.18.
Several analysts have released reports on the stock. Wells Fargo & Company assumed coverage of Cardlytics stocks in a Tuesday, April 5 research report. They issued an “overweight” rating and a price target of $72.00 on the stock. Needham & Company LLC cut its price target on Cardlytics shares from $85.00 to $60.00 and set a “buy” rating on the stock in a Tuesday, May 3 research report. Finally, Craig Hallum cut his price target on Cardlytics shares from $70.00 to $50.00 in a Tuesday, May 3 research report.
The company has a debt ratio of 0.32, a quick ratio of 1.29 and a current ratio of 1.29. The company’s 50-day moving average price is $32.20 and its two-hundred-day moving average price is $50.94. The company has a market capitalization of $875.86 million, a price-earnings ratio of -11.36 and a beta of 2.49.
Cardlytics (NASDAQ:CDLX – Get Rating) last released its results on Monday, May 2. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.36. Cardlytics had a negative net margin of 25.06% and a negative return on equity of 13.81%. The company posted revenue of $67.93 million for the quarter, versus analyst estimates of $65.84 million. During the same period of the previous year, the company achieved EPS of ($0.59). As a group, equity research analysts expect Cardlytics, Inc. to post -2.95 EPS for the current year.
In related news, director Scott D. Grimes sold 4,098 shares of the company in a trade that took place on Tuesday, April 19. The shares were sold at an average price of $50.09, for a total transaction of $205,268.82. Following the completion of the sale, the director now directly owns 243,606 shares of the company, valued at $12,202,224.54. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Additionally, director John V. Balen purchased 5,000 shares of the company in a transaction that took place on Friday, May 27. The shares were acquired at an average cost of $27.40 per share, with a total value of $137,000.00. Following the completion of the purchase, the director now owns 41,798 shares of the company, valued at $1,145,265.20. Disclosure of this purchase can be found here. In the past 90 days, insiders have sold 38,800 shares of the company worth $1,388,497. Insiders of the company hold 3.70% of the shares of the company.
A number of hedge funds and other institutional investors have recently changed their holdings in CDLX. Marshall Wace LLP acquired a new position in Cardlytics during the first quarter worth $336,000. FMR LLC increased its stake in Cardlytics by 2.3% in the first quarter. FMR LLC now owns 3,284,572 shares of the company valued at $54,327,000 after acquiring an additional 72,847 shares in the last quarter. Dark Forest Capital Management LP acquired a new position in Cardlytics in the third quarter worth approximately $39,000. Invesco Ltd. raised its position in Cardlytics by 20.1% in Q3. Invesco Ltd. now owns 15,850 shares of the company valued at $1,331,000 after purchasing an additional 2,651 shares in the last quarter. Finally, the Royal Bank of Canada increased its stake in Cardlytics by 232.5% in the third quarter. Royal Bank of Canada now owns 1,789 shares of the company valued at $150,000 after purchasing an additional 1,251 shares during the period. Hedge funds and other institutional investors hold 97.57% of the company’s shares.
About Cardlytics (NASDAQ: CDLX)
Cardlytics, Inc operates an advertising platform in the United States and United Kingdom. It offers the Cardlytics platform, an exclusive native banking advertising channel that enables marketers to reach customers through their network of partner financial institutions through digital channels, such as online, mobile apps, e- emails and various notifications in real time; and the Bridg Platform, a customer data platform that uses point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing. .
Receive news and reviews for Cardlytics Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Cardlytics and related companies with MarketBeat.com’s free daily email newsletter.